[HTML][HTML] Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
Abstract Mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors have shown single-agent
activity in relapsed/refractory acute myeloid leukemia (AML), even though most patients …
activity in relapsed/refractory acute myeloid leukemia (AML), even though most patients …
Landscape of tumor suppressor mutations in acute myeloid leukemia
C Panuzzo, E Signorino, C Calabrese, MS Ali… - Journal of clinical …, 2020 - mdpi.com
Acute myeloid leukemia is mainly characterized by a complex and dynamic genomic
instability. Next-generation sequencing has significantly improved the ability of diagnostic …
instability. Next-generation sequencing has significantly improved the ability of diagnostic …
Targeted therapy development in acute myeloid leukemia
TM Totiger, A Ghoshal, J Zabroski, A Sondhi, S Bucha… - Biomedicines, 2023 - mdpi.com
Therapeutic developments targeting acute myeloid leukemia (AML) have been in the
pipeline for five decades and have recently resulted in the approval of multiple targeted …
pipeline for five decades and have recently resulted in the approval of multiple targeted …
New strategies for the treatment of acute myelogenous leukemia: differentiation induction—present use and future possibilities
Ø Bruserud, BT Gjertsen - Stem cells, 2000 - academic.oup.com
A differentiation block and an accumulation of immature myeloid cells characterize acute
myelogenous leukemia (AML). However, native AML cells usually show some …
myelogenous leukemia (AML). However, native AML cells usually show some …
New perspectives in treating acute myeloid leukemia: driving towards a patient-tailored strategy
F Andreozzi, F Massaro, S Wittnebel… - International journal of …, 2022 - mdpi.com
For decades, intensive chemotherapy (IC) has been considered the best therapeutic option
for treating acute myeloid leukemia (AML), with no curative option available for patients who …
for treating acute myeloid leukemia (AML), with no curative option available for patients who …
Gefitinib induces myeloid differentiation of acute myeloid leukemia
Cure rates for patients with acute myeloid leukemia (AML) remain low despite ever-
increasing dose intensity of cytotoxic therapy. In an effort to identify novel approaches to …
increasing dose intensity of cytotoxic therapy. In an effort to identify novel approaches to …
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia
T Haferlach - ASH Education Program Book, 2008 - ashpublications.org
The heterogeneity of acute myeloid leukemia (AML) results from a complex network of
cytogenetic aberrations and molecular mutations. These genetic markers are the basis for …
cytogenetic aberrations and molecular mutations. These genetic markers are the basis for …
LSD1 inhibition exerts its antileukemic effect by recommissioning PU. 1-and C/EBPα-dependent enhancers in AML
Epigenetic regulators are recurrently mutated and aberrantly expressed in acute myeloid
leukemia (AML). Targeted therapies designed to inhibit these chromatin-modifying enzymes …
leukemia (AML). Targeted therapies designed to inhibit these chromatin-modifying enzymes …
Advances in targeted therapy for acute myeloid leukaemia
S Kayser, MJ Levis - British journal of haematology, 2018 - Wiley Online Library
In the past few years, research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
Leukemia: stem cells, maturation arrest, and differentiation therapy
S Sell - Stem cell reviews, 2005 - Springer
Human myeloid leukemias provide models of maturation arrest and differentiation therapy of
cancer. The genetic lesions of leukemia result in a block of differentiation (maturation arrest) …
cancer. The genetic lesions of leukemia result in a block of differentiation (maturation arrest) …